Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01755702 · ClinicalTrials.gov registry record · Phase 2
Paracetamol With Caffeine to Treat Episodic Tension Type Headache
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT01755702: Clinical Trial Phase 2 study, sponsored by GlaxoSmithKline.
NCT01755702 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 66 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01755702, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
This study will compare a fast-absorbing paracetamol plus caffeine formula with placebo and an over-the-counter dose of paracetamol and ibuprofen to treat episodic tension headache.
Primary Outcome
Time to first perceptible pain relief, calculated as time when partcipant selected 'a little' pain relief in the electronic pad minus the time of treatment. If this time was not available in the electronic pad then the earliest time corresponding to a pain relief score 1 or greater was recorded as time to 'a little' pain relief.
Interventions
- DRUG Placebo
- DRUG Paracetamol marketed formulation
- DRUG Experimental paracetamol + caffeine formulation
- DRUG ibuprofen marketed formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Why NCT01755702 stopped before completion
NCT01755702 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01755702 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01755702 about?
NCT01755702 is a clinical study titled "Paracetamol With Caffeine to Treat Episodic Tension Type Headache". This study will compare a fast-absorbing paracetamol plus caffeine formula with placebo and an over-the-counter dose of paracetamol and ibuprofen to treat episodic tension headache.
What is the current status of trial NCT01755702?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2009-07. Estimated completion is 2010-03.
What interventions are being tested in trial NCT01755702?
The interventions under investigation include: Placebo (DRUG), Paracetamol marketed formulation (DRUG), Experimental paracetamol + caffeine formulation (DRUG), ibuprofen marketed formulation (DRUG).
Who is sponsoring clinical trial NCT01755702?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01755702's enrollment target sits among peer trials
66 975th of 2000 higher than 1,014 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia